NEW VICE PRESIDENT FOR CORPORATE SUPPORT NAMED
David Kinsaul announced that effective January 2, 2008 Lisa Coffey will
replace Bonnie Sommerville as the vice president for corporate support.
Since arriving at Dayton Children’s in 1988 Lisa has served in several
important leadership positions, including director of ambulatory services.
Lisa will have responsibility for facilities, information resources,
dietary and material services. In addition, Mr. Kinsaul announced some
organizational changes to the Dayton Children’s structure. For more
information contact Tom Murphy, MD, at 937-641-5871.
Dayton Children’s has been asked to participate in a new vaccine trial.
The study is investigating the use of a meningococcal conjugate vaccine in
healthy toddlers. The study ideally should be performed in a community
practice setting. Assistance from Dayton Children's research group will
be provided to help run the trial. Compensation is provided both to the
physician, clinical investigator and to study patients. If your practice
might be interested in participating in this trial or if you need
additional information, please contact either Sherman Alter, MD, at
937-641-3329 or Linda Uhl at 937-641-4467.
THE JOINT COMMISSION
The Joint Commission and the Centers for Medicaid and Medicare Services
want to assure that you, as physicians, are aware that you have a right to
file a complaint with either agency if you feel that there are concerns
with the quality of care at Dayton Children’s. It is important that you
know that there will be no retaliation from the hospital if you file a
formal complaint. We do, however, encourage you to try to resolve issues
through the appropriate channels within the organization first. You can
always contact any member of senior management if you have a concern. The
following are telephone/web address contact points:
Centers for Medicare and Medicaid Services The Joint Commission
Ohio Department of Health Oakbrook, Illinois
Telephone: 1-800-342-0553 1-800-994-6610
THROMBOPHILIA MUTATION DETECTION
As of November 5, 2007, testing for the thrombophilia mutations, Factor V
Leiden (R506Q) Prothrombin G20210A and Methylenetetrahydrofolate reductase
(MTHFR) C677T, will be done using the AutoGenomics INFINITI molecular
diagnostic testing platform. Additionally, a second MTHFR mutation,
A1298C, will now be detected. This platform includes a multiplex PCR to
amplify all the thrombophilia mutations above in a single reaction followed
by automated detection by microarray hybridization after directed primer
Please use the following Sunquest test codes to order these tests – THROM
for the complete panel; 5FLE for Factor V Leiden; PRT for Prothrombin
G20210A and MTHFRB for MTHFR C677T and A1298C.
For this assay, we require 1-3mL (0.5mL minimum) whole blood in an EDTA
(purple top) tube. Specimens will be batched and the assay performed
weekly. Results will be reported within seven days of receipt of
specimen. If you have any questions, please contact the genetics
department at 937-641-3262.
Finding the latest trusted child health and safety information doesn't have to be hard. Pediatric Link, Dayton Children's e-newsletter offers timely and up-to-date information for health care professionals from the experts you trust at Dayton Children's.